瑞替普酶联用参附注射液治疗120例AMI合并心力衰竭的临床疗效评价

Clinicla efficacy of reteplase combined with Shenfu Injection for AMI complicated with heartfailure（120 cases）

目的：探讨瑞替普酶联用参附注射液治疗急性心肌梗死合并心衰的临床疗效。方法：选取2010年1月～2014年3月就诊于本院的急性心肌梗死合并心衰患者203例为研究对象，将其随机分为2组，对照组83例予瑞替普酶进行治疗，观察组120例予瑞替普酶联用参附注射液进行治疗。然后对2组患者再通时间及再通率，治疗前后心肌肌钙蛋白水平和并发症发生情况进行统计及比较。结果：2组患者再通时间及再通率的比较、心肌肌钙蛋白水平治疗后第7天及治疗后第15天，P＜0．05，存在统计学差异，心肌肌钙蛋白水平治疗前、治疗后第1天和并发症发生情况，P＞0．05，无统计学意义。结论：瑞替普酶联用参附注射液治疗急性心肌梗死合并心衰的临床疗效要优于单用瑞替普酶，且安全性好，建议在临床上推广应用。

Objective：To investigate the clinical effect of reteplase combined with Shenfu Injection for acute myocardial infarction com-plicated with heart failure.Methods：From 2010 January^2014 March,203 cases with acute myocardial infarction complicated with heart failure in our hospital were selected as the research object, and were randomly divided into 2 groups, 83 cases in the control group were trea-ted with reteplase, the observation group（120 cases） were treated with reteplase combined with Shenfu injection treatment.Then the two groups of patients with recanalization time and recanalization rate before and after treatment, and postoperative complication incidence of car-diac troponin T were analyzed and compared.Results：Two groups of patients with recanalization time and comparison, the recanalization rate of cardiac troponin levels after treatment in seventh days 1 and fifteenth days after treatment, P〈0.05, there was significant difference in incidence of complications, first day and cardiac troponin levels before treatment, after treatment, P＆gt;0.05, no statistical significance. Conclusion：Compared with reteplase only,the clinical curative effect of reteplase combined with Shenfu Injection in the treatment of acute myocardial infarction complicated with heart failure was better, and the security should be good, recommended in clinical application.